Stability Summary — GLPI-103
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The stability summary — how the substance and product change over time and the resulting shelf life and storage conditions.
Why it exists. The expiry date and storage statement on the label come from stability studies run under ICH Q1 conditions. This summarizes that data and justifies the shelf life.
How it is produced here. No real manufacturing was done, so the chemistry, manufacturing, and controls detail is deep-knowledge mock — realistic, standard-conformant content standing in for real CMC data.
Format & governing standard. ICH Q1A(R2) · Q1B · Q1D · Q1E · Q5C · Q3B(R2)
Stability Summary — GLPI-103
| Field | Value |
|---|---|
| Document ID | M3-STAB |
| Version | 2.0 (expanded) |
| Standard | ICH Q1A(R2) · Q1B · Q1D · Q1E · Q5C · Q3B(R2) |
| Confidentiality | Confidential |
[MOCK — deep-knowledge assumption]Stability protocols, data summary, degradation analysis, and shelf-life/retest justification for the drug substance and both drug products.
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | CMC / Stability | Initial |
| 2.0 | 2026-06-30 | CMC / Stability | Expanded — full study design, datasets, degradation pathways, Q1E regression, storage statements, commitment |
1. Study Design (Q1A(R2)/Q1D)
| Condition | Drug substance (−20 °C) | IV product (2–8 °C) | Oral product (≤30 °C) |
|---|---|---|---|
| Long-term | −20 °C, ≥24 mo | 5 °C, ≥24 mo | 25 °C/60% RH, ≥24 mo |
| Intermediate | 5 °C | — | 30 °C/65% RH |
| Accelerated | 25 °C/60% RH, 6 mo | 25 °C, 6 mo | 40 °C/75% RH, 6 mo |
| Batches | 3 registration | 3 | 3 |
| Bracketing/matrixing (Q1D) applied across strengths/container sizes where justified. Stability-indicating methods: RP-HPLC (assay/related substances), SE-HPLC (aggregates), plus appearance, water (KF), pH, dissolution (oral), preservative content, sub-visible particles/sterility/endotoxin (IV). |
2. Data Summary (illustrative — long-term)
| Attribute | Drug substance (−20 °C, 0→24 mo) | IV (5 °C, 0→24 mo) | Oral (25 °C, 0→24 mo) |
|---|---|---|---|
| Assay (%) | 99.4 → 98.8 | 99.8 → 98.3 | 99.1 → 97.4 |
| Total related substances (%) | 1.0 → 1.4 | 1.4 → 2.8 | 1.8 → 3.2 |
| Aggregates (%) | 0.4 → 0.6 | 0.6 → 1.2 | n/a |
| Dissolution (oral, % at 30 min) | — | — | 94 → 90 |
| Water (%) | 6.8 → 7.2 | — | 3.0 → 4.1 |
| Sterility / endotoxin (IV) | — | conforms | — |
All attributes remained within the proposed specifications at long-term conditions through 24 months; accelerated conditions showed the expected, controlled increase in related substances/aggregates (substance/IV) and moisture-mediated change (oral), informing handling and packaging.
Out-of-trend investigation (QA-003 ISS-008): an oral-tablet batch at 40 °C/75% RH trended toward the related-substances limit by 6 months. Root cause = moisture ingress (desiccant capacity insufficient for the hygroscopic SNAC/peptide tablet). Assessment confirmed no impact on long-term (≤30 °C) shelf life; CAPA moved the primary pack to an Alu/Alu blister (with increased desiccant for the HDPE-bottle presentation) and tightened the water-content release limit — a worked example of stability issue management.
3. Degradation Pathways
Principal pathways, confirmed by forced-degradation (acid/base/oxidative/thermal/photolytic) with peak-purity: oxidation (Met/Trp), deamidation (Asn→isoAsp), aggregation/dimerisation (substance and IV), and moisture-mediated hydrolysis of the peptide/enhancer in the tablet. Each degradant is tracked by the stability-indicating method and qualified (Q3B).
4. Photostability & In-Use
Photostability (Q1B) showed the bulk substance and unprotected solution are light-sensitive; the container-closure provides adequate protection. In-use stability supports a 6-week period for the multidose IV pen at ≤30 °C after first use, and once-opened conditions for the desiccated oral bottle.
5. Shelf-Life / Retest Justification (Q1E)
The expiry date and storage instructions on the label are not guesses — they are read off stability studies that store the product under controlled conditions and track when it starts to change. This section is that justification.
Statistical evaluation (regression with poolability testing across batches; extrapolation per Q1E) supports:
- Drug substance: re-test period 24 months at −20 °C.
- IV product: shelf life 24 months at 2–8 °C (do not freeze).
- Oral product: shelf life 24 months at ≤30 °C, protected from moisture (keep desiccant). A post-approval commitment (ongoing) stability programme continues on the first commercial batches and ≥1 batch/year thereafter.
Comments (0)
No comments yet. Be the first to say something!